Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


April 01, 2015 5:44 PM ET

Biotechnology

Company Overview of Ardelyx, Inc.

Company Overview

Ardelyx, Inc. discovers, develops, and commercializes minimally-systemic small molecule therapeutics for the gastrointestinal (GI) tract to treat cardio-renal, GI, and metabolic diseases. Its lead product candidate is tenapanor, a small molecule NHE3 inhibitor, which has completed Phase 2b clinical trial for the treatment of patients with constipation-predominant irritable bowel syndrome and hyperphosphatemic patients with chronic kidney disease on dialysis, as well as Phase 2a clinical trial in patients with late-stage chronic kidney disease. The company’s discovery and lead development programs that are in research phase include RDX002 NaP2b inhibitor for hyperphosphatemia; RDX009 TGR5 ago...

34175 Ardenwood Boulevard

Suite 100

Fremont, CA 94555

United States

Founded in 2007

34 Employees

Phone:

510-745-1700

Fax:

510-745-0493

Key Executives for Ardelyx, Inc.

Chief Executive Officer, President and Director
Age: 49
Total Annual Compensation: $416.3K
Senior Vice President of Drug Development
Age: 53
Total Annual Compensation: $277.5K
Compensation as of Fiscal Year 2013.

Ardelyx, Inc. Key Developments

Ardelyx, Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 09:30 AM

Ardelyx, Inc. Presents at BioCentury 22nd Annual Future Leaders in the Biotech Industry Conference, Mar-20-2015 09:30 AM. Venue: Millennium Broadway Hotel & Conference Center, New York, New York, United States. Speakers: Michael G. Raab, Chief Executive Officer, President and Director.

Ardelyx, Inc. Announces Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014

Ardelyx, Inc. announced unaudited earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company announced total revenue of $6,338,000 compared to $8,488,000 for the same period a year ago. Loss from operations was $3,932,000 compared to $718,000 for the same period a year ago. Net loss and comprehensive loss was $3,970,000 compared to $4,269,000 for the same period a year ago. Basic and diluted net loss per share was $0.21 compared to $3.53 for the same period a year ago. For the full year, the company announced total revenue of $31,623,000 compared to $28,928,000 for the same period a year ago. Loss from operations was $1,564,000 compared to $2,865,000 for the same period a year ago. Net loss and comprehensive loss was $3,214,000 compared to $6,564,000 for the same period a year ago. Basic and diluted net loss per share was $0.31 compared to $5.82 for the same period a year ago. Increase in revenue for both the full year and the fourth quarter was primarily due to the amortization of deferred revenue from a $15.0 million development milestone payment that the company received in December 2013 and a milestone payment of $25.0 million that the company received in May 2014.

Ardelyx, Inc. to Report Q4, 2014 Results on Feb 25, 2015

Ardelyx, Inc. announced that they will report Q4, 2014 results at 1:01 PM, GMT Standard Time on Feb 25, 2015

Similar Private Companies By Industry

Company Name Region
Twentyfirst Century Biochemicals, Inc. United States
Genomic Expression Inc. United States
Modular Genetics, Inc. United States
AnaptysBio, Inc. United States
Agilvax, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Ardelyx, Inc., please visit www.ardelyx.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.